The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.
Novel allele-dependent role for APOE in controlling the rate of synapse pruning by astrocytes
Open accessAbstract
Significance: Susceptibility to Alzheimer’s disease (AD) is strongly controlled by apolipoprotein E ( APOE ) genotype. The E4 allele greatly increases risk whereas the E2 allele decreases risk, but it is not known how the APOE allele controls AD risk. In this paper, we report a novel role for APOE by showing that APOE2 enhances and APOE4 decreases the rate of synapse pruning and turnover in the brain by astrocytes. We also show that APOE alleles control the rate of accumulation of the complement C1q protein, which we hypothesize, reflects senescent synapse accumulation during normal brain aging and vulnerability of the aging brain to neurodegenerative diseases such as AD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“Previous studies have shown that expression of human APOE4 can enhance C1q accumulation and increase astrocyte-mediated synaptic pruning in mouse brain (Chung, Verghese et al. 2016); similarly, iPSC-derived APOE4/E4 organoids feature enhanced apoptosis and impaired synaptic integrity compared to APOE3/E3 organoids (Zhao, Fu et al. 2020).”
From SORLA up-regulation suppresses pathological effects in aged tauopathy mouse brain (2026) · cites this paper as Chung, Verghese et al. 2016
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“and that it is involved in the regulation of synaptic pruning, which suggests a key role for astrocytic apoE in synaptic integrity [49].”
From APOE4 genotype exacerbates the depression-like behavior of mice during aging through ATP decline (2021) · cites this paper as [49]
In the citing paper
“ApoE isoforms differentially affect this process, with ApoE4 limiting the ability of astrocytes to prune synapses [76, 77].”
From ApoE, ApoE Receptors, and the Synapse in Alzheimer's Disease (2017) · cites this paper as [77]
In the citing paper
“in knock-in mice expressing human apoE variants, the apoE4 risk allele increases C1q accumulation relative to apoE2 (Chung et al., 2016).”
From Microglia in Alzheimer’s disease (2018) · cites this paper as Chung et al., 2016
In the citing paper
“another recent publication reported C1q deposition was dependent on ApoE isoforms, with aged human ApoEε4 knock-in mice accumulating significantly more C1q in the hippocampus than ApoEε2 mice.”
From Glial contributions to neurodegeneration in tauopathies (2017) · cites this paper as [166]
In the citing paper
“Additionally, ApoEε2 enhanced synapse elimination by astrocytes while ApoEε4 prevented it [166].”
From Glial contributions to neurodegeneration in tauopathies (2017) · cites this paper as [166]
In the citing paper
“Since microglia and astrocytes, both of which express complement, are highly phagocytic and participate in synapse pruning (10, 43)”
From Complement C3 deficiency protects against neurodegeneration in aged plaque-rich APP/PS1 mice (2017) · cites this paper as [43]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Amyloid oligomers exacerbate tau pathology in a mouse model of tauopathy
Selenica, M.-L. B., Brownlow, M., Jimenez, J. P., Lee, D. C., Pena, G., Dickey, C. A., Gordon, M. N., & Morgan, D. (2013) · Neurodegenerative Diseases · doi:10.1159/000337230 · Cited by 10,359
Corder, E. H., Saunders, A. M., Strittmatter, W. J., Schmechel, D. E., Gaskell, P. C., Small, G. W., Roses, A. D., Haines, J. L., & Pericak-Vance, M. A. (1993) · Science · doi:10.1126/science.8346443 · Cited by 9,429
Alzheimer's Disease Is a Synaptic Failure
Selkoe, D. J. (2002) · Science · doi:10.1126/science.1074069 · Cited by 4,420
Microglia Sculpt Postnatal Neural Circuits in an Activity and Complement-Dependent Manner
Schafer, D. P., Lehrman, E. K., Kautzman, A. G., Koyama, R., Mardinly, A. R., Yamasaki, R., Ransohoff, R. M., Greenberg, M. E., Barres, B. A., & Stevens, B. (2012) · Neuron · doi:10.1016/j.neuron.2012.03.026 · Cited by 4,089
Self-citationApolipoprotein E: Cholesterol Transport Protein with Expanding Role in Cell Biology
Mahley, R. W. (1988) · Science · doi:10.1126/science.3283935 · Cited by 4,028
Preparation of separate astroglial and oligodendroglial cell cultures from rat cerebral tissue.
McCarthy, K. D., & de Vellis, J. (1980) · The Journal of Cell Biology · doi:10.1083/jcb.85.3.890 · Cited by 3,845
Complement and microglia mediate early synapse loss in Alzheimer mouse models
Hong, S., Beja-Glasser, V. F., Nfonoyim, B. M., Frouin, A., Li, S., Ramakrishnan, S., Merry, K. M., Shi, Q., Rosenthal, A., Barres, B. A., et al. (2016) · Science · doi:10.1126/science.aad8373 · Cited by 3,343 · cited 2×
“Moreover, a recent study has shown that the profound loss of synapses at the early stages of AD could be prevented by blocking activation of the complement cascade (38).”
BackgroundSelf-citationThe Classical Complement Cascade Mediates CNS Synapse Elimination
Stevens, B., Allen, N. J., Vazquez, L. E., Howell, G. R., Christopherson, K. S., Nouri, N., Micheva, K. D., Mehalow, A. K., Huberman, A. D., Stafford, B., et al. (2007) · Cell · doi:10.1016/j.cell.2007.10.036 · Cited by 3,313
Self-citationCahoy, J. D., Emery, B., Kaushal, A., Foo, L. C., Zamanian, J. L., Christopherson, K. S., Xing, Y., Lubischer, J. L., Krieg, P. A., Krupenko, S. A., et al. (2008) · The Journal of Neuroscience · doi:10.1523/jneurosci.4178-07.2008 · Cited by 3,129
Self-citationProtective effect of apolipoprotein E type 2 allele for late onset Alzheimer disease
Corder, E. H., Saunders, A. M., Risch, N. J., Strittmatter, W. J., Schmechel, D. E., Gaskell, P. C., Rimmler, J. B., Locke, P. A., Conneally, P. M., Schmader, K. E., et al. (1994) · Nature Genetics · doi:10.1038/ng0694-180 · Cited by 1,920
Research works printed but not linked: 1
- B Teter, Apolipoprotein E isotype-specific effects in neurodegeneration. Alzheimers Rep 3, 199–212 (2000).
Cited by
Sorted by citations
Microglia in Alzheimer’s disease
Hansen, D. V., Hanson, J. E., & Sheng, M. (2018) · Journal of Cell Biology · doi:10.1083/jcb.201709069 · Cited by 1,935
“Interestingly, in knock-in mice expressing human apoE variants, the apoE4 risk allele increases C1q accumulation relative to apoE2 (Chung et al., 2016).”
BackgroundAPOE and Alzheimer’s disease: Advances in genetics, pathophysiology, and therapeutic approaches
Serrano-Pozo, A., Das, S., & Hyman, B. T. (2021) · The Lancet Neurology · doi:10.1016/s1474-4422(20)30412-9 · Cited by 1,037
Self-citationInterplay between innate immunity and Alzheimer disease: APOE and TREM2 in the spotlight
Shi, Y., & Holtzman, D. M. (2018) · Nature Reviews Immunology · doi:10.1038/s41577-018-0051-1 · Cited by 595
Self-citationComplement C3 deficiency protects against neurodegeneration in aged plaque-rich APP/PS1 mice
Shi, Q., Chowdhury, S., Ma, R., Le, K. X., Hong, S., Caldarone, B. J., Stevens, B., & Lemere, C. A. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aaf6295 · Cited by 593
“Given that microglia and astrocytes, both of which express complement, are highly phagocytic and participate in synapse pruning (10, 43), our findings that C3 deficiency protected against hippocampal synaptic decline in two mouse models (C3 KO and APP/PS1;C3 KO) suggest that complement C3 or its downstream activation…”
BackgroundWerneburg, S., Jung, J., Kunjamma, R. B., Ha, S.-K., Luciano, N. J., Willis, C. M., Gao, G., Biscola, N. P., Havton, L. A., Crocker, S. J., et al. (2020) · Immunity · doi:10.1016/j.immuni.2019.12.004 · Cited by 440
Microglia modulate neurodegeneration in Alzheimer’s and Parkinson’s diseases
Bartels, T., De Schepper, S., & Hong, S. (2020) · Science · doi:10.1126/science.abb8587 · Cited by 412
Glial contributions to neurodegeneration in tauopathies
Leyns, C. E. G., & Holtzman, D. M. (2017) · Molecular Neurodegeneration · doi:10.1186/s13024-017-0192-x · Cited by 409
Self-citationApoE4: an emerging therapeutic target for Alzheimer’s disease
Safieh, M., Korczyn, A. D., & Michaelson, D. M. (2019) · BMC Medicine · doi:10.1186/s12916-019-1299-4 · Cited by 449
Rodent models for Alzheimer disease
Götz, J., Bodea, L., & Goedert, M. (2018) · Nature reviews. Neuroscience · doi:10.1038/s41583-018-0054-8 · Cited by 422
Astrocyte Heterogeneity: Impact to Brain Aging and Disease
Matias, I., Morgado, J., & Gomes, F. C. A. (2019) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2019.00059 · Cited by 387
Microglia-Mediated Synapse Loss in Alzheimer's Disease
Rajendran, L., & Paolicelli, R. C. (2018) · The Journal of Neuroscience · doi:10.1523/jneurosci.1136-17.2017 · Cited by 355
Involvement of Lipids in Alzheimer’s Disease Pathology and Potential Therapies
Chew, H., Solomon, V. A., & Fonteh, A. N. (2020) · Frontiers in Physiology · doi:10.3389/fphys.2020.00598 · Cited by 353
Beyond the neuron–cellular interactions early in Alzheimer disease pathogenesis
Henstridge, C. M., Hyman, B. T., & Spires-Jones, T. L. (2019) · Nature Reviews Neuroscience · doi:10.1038/s41583-018-0113-1 · Cited by 348
Self-citationErrant gardeners: glial-cell-dependent synaptic pruning and neurodevelopmental disorders
Neniškytė, U., & Gross, C. T. (2017) · Nature reviews. Neuroscience · doi:10.1038/nrn.2017.110 · Cited by 322
Phagocytosis in the Brain: Homeostasis and Disease
Galloway, D. A., Phillips, A. E. M., Owen, D. R., & Moore, C. S. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00790 · Cited by 319
APOE2: protective mechanism and therapeutic implications for Alzheimer’s disease
Li, Z., Shue, F., Zhao, N., Shinohara, M., & Bu, G. (2020) · Molecular Neurodegeneration · doi:10.1186/s13024-020-00413-4 · Cited by 306
Microglial phagocytosis of neurons in neurodegeneration, and its regulation
Butler, C. A., Popescu, A. S., Kitchener, E. J. A., Allendorf, D. H., Puigdellívol, M., & Brown, G. C. (2021) · Journal of Neurochemistry · doi:10.1111/jnc.15327 · Cited by 295
ApoE facilitates the microglial response to amyloid plaque pathology
Ulrich, J. D., Ulland, T. K., Mahan, T. E., Nyström, S., Nilsson, K. P., Song, W. M., Zhou, Y., Reinartz, M., Choi, S., Jiang, H., et al. (2018) · Journal of Experimental Medicine · doi:10.1084/jem.20171265 · Cited by 297
Self-citationThe good, the bad, and the opportunities of the complement system in neurodegenerative disease
Schartz, N. D., & Tenner, A. J. (2020) · Journal of Neuroinflammation · doi:10.1186/s12974-020-02024-8 · Cited by 298
Deciphering the astrocyte reaction in Alzheimer's disease
Perez-Nievas, B. G., & Serrano-Pozo, A. (2018) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2018.00114 · Cited by 282
Fernandez, C. G., Hamby, M. E., McReynolds, M. L., & Ray, W. J. (2019) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2019.00014 · Cited by 277
Astrocytic LRP1 Mediates Brain Aβ Clearance and Impacts Amyloid Deposition
Liu, C.-C., Hu, J., Zhao, N., Wang, J., Wang, N., Cirrito, J. R., Kanekiyo, T., Holtzman, D. M., & Bu, G. (2017) · The Journal of Neuroscience · doi:10.1523/jneurosci.3442-16.2017 · Cited by 267
Self-citationApolipoprotein E and Alzheimer’s disease: Findings, hypotheses, and potential mechanisms
Koutsodendris, N., Nelson, M. R., Rao, A., & Huang, Y. (2022) · Annual Review of Pathology Mechanisms of Disease · doi:10.1146/annurev-pathmechdis-030421-112756 · Cited by 231
Untangling Genetic Risk for Alzheimer’s Disease
Pimenova, A. A., Raj, T., & Goate, A. M. (2018) · Biological Psychiatry · doi:10.1016/j.biopsych.2017.05.014 · Cited by 223
Phagocytic clearance of presynaptic dystrophies by reactive astrocytes in Alzheimer's disease
Gomez‐Arboledas, A., Davila, J. C., Sanchez‐Mejias, E., Navarro, V., Nuñez‐Diaz, C., Sanchez‐Varo, R., Sanchez‐Mico, M. V., Trujillo‐Estrada, L., Fernandez‐Valenzuela, J. J., Vizuete, M., et al. (2018) · Glia · doi:10.1002/glia.23270 · Cited by 220
Cell type‐specific roles of APOE4 in Alzheimer disease
Blumenfeld, J., Yip, O., Kim, M. J., & Huang, Y. (2024) · Nature Reviews Neuroscience · doi:10.1038/s41583-023-00776-9 · Cited by 202
Phagocytic microglia and macrophages in brain injury and repair
Yu, F., Wang, Y., Stetler, R. A., Leak, R. K., Hu, X., & Chen, J. (2022) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.13899 · Cited by 213
Amyloid clearance defect in ApoE4 astrocytes is reversed by epigenetic correction of endosomal pH
Prasad, H., & Rao, R. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1801612115 · Cited by 207
Lee, S., Devanney, N. A., Golden, L. R., Smith, C. T., Schwartz, J. L., Walsh, A. E., Clarke, H. A., Goulding, D. S., Allenger, E. J., Morillo-Segovia, G., et al. (2023) · Cell Reports · doi:10.1016/j.celrep.2023.112196 · Cited by 203
The Role of Complement in Synaptic Pruning and Neurodegeneration
Gómez-Arboledas, Á., Acharya, M. M., & Tenner, A. J. (2021) · ImmunoTargets and Therapy · doi:10.2147/itt.s305420 · Cited by 216
Intersection of pathological tau and microglia at the synapse
Vogels, T., Murgoci, A.-N., & Hromádka, T. (2019) · Acta Neuropathologica Communications · doi:10.1186/s40478-019-0754-y · Cited by 197
Alzheimer’s Disease, Oligomers, and Inflammation
Forloni, G., & Balducci, C. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-170819 · Cited by 205
Meftah, S., & Gan, J. (2023) · Frontiers in Synaptic Neuroscience · doi:10.3389/fnsyn.2023.1129036 · Cited by 205
Apolipoprotein E metabolism and functions in brain and its role in Alzheimer's disease
Liao, F., Yoon, H., & Kim, J. (2017) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000383 · Cited by 191
MFG‐E8 reverses microglial‐induced neurotoxic astrocyte (A1) via NF‐κB and PI3K‐Akt pathways
Xu, X., Zhang, A., Zhu, Y., He, W., Di, W., Fang, Y., & Shi, X. (2018) · Journal of Cellular Physiology · doi:10.1002/jcp.26918 · Cited by 193
Vilalta, A., & Brown, G. C. (2017) · FEBS Journal · doi:10.1111/febs.14323 · Cited by 180
The synapse as a treatment avenue for Alzheimer’s Disease
Peng, L., Bestard‐Lorigados, I., & Song, W. (2022) · Molecular Psychiatry · doi:10.1038/s41380-022-01565-z · Cited by 162
ApoE, ApoE Receptors, and the Synapse in Alzheimer's Disease
Lane-Donovan, C., & Herz, J. (2017) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2016.12.001 · Cited by 157
“Astrocytes actively partake in synaptic pruning by phagocytosing synaptosomes, and ApoE isoforms differentially affect this process, with ApoE4 limiting the ability of astrocytes to prune synapses [76, 77].”
BackgroundPires, M., & Rego, A. C. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24010778 · Cited by 157
Oksanen, M., Lehtonen, Š., Jaronen, M., Goldsteins, G., Hämäläinen, R. H., & Koıstınaho, J. (2019) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-019-03111-7 · Cited by 166
Tzioras, M., Davies, C., Newman, A., Jackson, R., & Spires‐Jones, T. (2019) · Neuropathology and Applied Neurobiology · doi:10.1111/nan.12529 · Cited by 147
Glial Contribution to Excitatory and Inhibitory Synapse Loss in Neurodegeneration
Henstridge, C. M., Tzioras, M., & Paolicelli, R. C. (2019) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2019.00063 · Cited by 155
Molecular Communication of a Dying Neuron in Stroke
Puig, B., Brenna, S., & Magnus, T. U. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19092834 · Cited by 146
Glutamatergic synaptic plasticity and dysfunction in Alzheimer disease: Emerging mechanisms
Benarroch, E. E. (2018) · Neurology · doi:10.1212/wnl.0000000000005807 · Cited by 115
3D culture models of Alzheimer’s disease: a road map to a “cure-in-a-dish”
Choi, S. H., Kim, Y. H., Quinti, L., Tanzi, R. E., & Kim, D. Y. (2016) · Molecular Neurodegeneration · doi:10.1186/s13024-016-0139-7 · Cited by 132
Transgenic Mouse Models of Alzheimer’s Disease: An Integrative Analysis
Sanchez-Varo, R. M., Mejias‐Ortega, M., Fernandez-Valenzuela, J. J., Nuñez‐Diaz, C., Cáceres-Palomo, L., Vegas‐Gomez, L., Sánchez‐Mejías, E., Trujillo‐Estrada, L., García‐León, J. A., Moreno‐González, I., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23105404 · Cited by 136
O’Leary, L. A., & Mechawar, N. (2021) · Glia · doi:10.1002/glia.23994 · Cited by 126
Synaptic Elimination in Neurological Disorders
Cardozo, P. L., de Lima, I. B. Q., Maciel, E. M. A., Silva, N. C., Dobránsky, T., & Ribeiro, F. M. (2019) · Current Neuropharmacology · doi:10.2174/1570159x17666190603170511 · Cited by 115
The Phagocytic Code Regulating Phagocytosis of Mammalian Cells
Cockram, T. O. J., Dundee, J. M., Popescu, A. S., & Brown, G. C. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.629979 · Cited by 117
Microglial efferocytosis: Diving into the Alzheimer’s disease gene pool
Romero-Molina, C., Garretti, F., Andrews, S. J., Marcora, E., & Goate, A. M. (2022) · Neuron · doi:10.1016/j.neuron.2022.10.015 · Cited by 111
Astroglia-specific contributions to the regulation of synapses, cognition and behaviour
Augusto‐Oliveira, M., Arrifano, G. D. P., Takeda, P. Y., Lopes-Araújo, A., Santos-Sacramento, L., Anthony, D. C., Verkhratsky, A., & Lopez, M. E. C. (2020) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2020.07.039 · Cited by 111
Jeong, W., Lee, H. G., Cho, S., & Seo, J. (2019) · PubMed · doi:10.14348/molcells.2019.0200 · Cited by 104
The role of APOE4 in Alzheimer’s disease: strategies for future therapeutic interventions
Hunsberger, H. C., Pinky, P. D., Smith, W., Suppiramaniam, V., & Reed, M. N. (2019) · Neuronal Signaling · doi:10.1042/ns20180203 · Cited by 94
Amyloid‐β impairs the phagocytosis of dystrophic synapses by astrocytes in Alzheimer's disease
Sanchez‐Mico, M. V., Jimenez, S., Gomez‐Arboledas, A., Muñoz‐Castro, C., Romero‐Molina, C., Navarro, V., Sanchez‐Mejias, E., Nuñez‐Diaz, C., Sanchez‐Varo, R., Galea, E., et al. (2021) · Glia · doi:10.1002/glia.23943 · Cited by 93
Phagocytic Roles of Glial Cells in Healthy and Diseased Brains
Jung, Y.-J., & Chung, W.-S. (2018) · Biomolecules & Therapeutics · doi:10.4062/biomolther.2017.133 · Cited by 89
Self-citationBrody, D. L., Jiang, H., Wildburger, N. C., & Esparza, T. J. (2017) · Alzheimer s Research & Therapy · doi:10.1186/s13195-017-0293-3 · Cited by 86
Dendritic Spines: Mediators of Cognitive Resilience in Aging and Alzheimer’s Disease
Walker, C. K., & Herskowitz, J. H. (2021) · The Neuroscientist · doi:10.1177/1073858420945964 · Cited by 86
Astrocyte‐mediated synapse remodeling in the pathological brain
Kim, S. K., Nabekura, J., & Koizumi, S. (2017) · Glia · doi:10.1002/glia.23169 · Cited by 89
Apolipoprotein E in Cardiometabolic and Neurological Health and Diseases
Alagarsamy, J., Jaeschke, A., & Hui, D. Y. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23179892 · Cited by 86
Initiative, A. D. N., Takahashi, H., Klein, Z. A., Bhagat, S. M., Kaufman, A. C., Kostylev, M. A., Ikezu, T., & Strittmatter, S. M. (2017) · Acta Neuropathologica · doi:10.1007/s00401-017-1668-z · Cited by 84
Luchena, C., Zuazo-Ibarra, J., Alberdi, E. M., Matute, C., & Capetillo‐Zarate, E. (2018) · Mediators of Inflammation · doi:10.1155/2018/2530414 · Cited by 84
HIV-associated synaptic degeneration
Ru, W., & Tang, S. (2017) · Molecular Brain · doi:10.1186/s13041-017-0321-z · Cited by 85
What are activated and reactive glia and what is their role in neurodegeneration?
Bennett, M. L., & Viaene, A. N. (2021) · Neurobiology of Disease · doi:10.1016/j.nbd.2020.105172 · Cited by 77
Geloso, M. C., & D’Ambrosi, N. (2021) · Cells · doi:10.3390/cells10030686 · Cited by 79
Ma, Y., & Zhou, X. (2024) · Nature Methods · doi:10.1038/s41592-024-02284-9 · Cited by 80
Wang, Y., Fu, A. K. Y., & Ip, N. Y. (2021) · FEBS Journal · doi:10.1111/febs.15878 · Cited by 75
Savas, J. N., Wang, Y.-Z., DeNardo, L. A., Martinez-Bartolome, S., McClatchy, D. B., Hark, T. J., Shanks, N. F., Cozzolino, K. A., Lavallée-Adam, M., Smukowski, S. N., et al. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.11.009 · Cited by 66
Association of APOE Genotype With Heterogeneity of Cognitive Decline Rate in Alzheimer Disease
Qian, J., Betensky, R. A., Hyman, B. T., & Serrano-Pozo, A. (2021) · Neurology · doi:10.1212/wnl.0000000000011883 · Cited by 71
Self-citationKLOTHO heterozygosity attenuates APOE4 -related amyloid burden in preclinical AD
Erickson, C. M., Schultz, S. A., Oh, J. M., Darst, B. F., Ma, Y., Norton, D., Betthauser, T., Gallagher, C. L., Carlsson, C. M., Bendlin, B. B., et al. (2019) · Neurology · doi:10.1212/wnl.0000000000007323 · Cited by 70
Synaptic pruning through glial synapse engulfment upon motor learning
Morizawa, Y. M., Matsumoto, M., Nakashima, Y., Endo, N., Aida, T., Ishikane, H., Beppu, K., Moritoh, S., Inada, H., Osumi, N., et al. (2022) · Nature Neuroscience · doi:10.1038/s41593-022-01184-5 · Cited by 75
Uncovering Disease Mechanisms in a Novel Mouse Model Expressing Humanized APOEε4 and Trem2*R47H
Kotredes, K. P., Oblak, A., Pandey, R. S., Lin, P. B.-C., Garceau, D., Williams, H., Uyar, A., O’Rourke, R., O’Rourke, S., Ingraham, C., et al. (2021) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.735524 · Cited by 66
Alzheimer's Disease and Sleep–Wake Disturbances: Amyloid, Astrocytes, and Animal Models
Vanderheyden, W. M., Lim, M. M., Musiek, E. S., & Gerstner, J. R. (2018) · Journal of Neuroscience · doi:10.1523/jneurosci.1135-17.2017 · Cited by 64
Cognitive Impairment in Older Adults and Therapeutic Strategies
Montine, T. J., Bukhari, S. A., & White, L. R. (2020) · Pharmacological Reviews · doi:10.1124/pharmrev.120.000031 · Cited by 67
La Cunza, N., Tan, L. X., Thamban, T., Germer, C. J., Rathnasamy, G., Toops, K. A., & Lakkaraju, A. (2021) · JCI Insight · doi:10.1172/jci.insight.142254 · Cited by 65
The Role of Astrocytes in Synapse Loss in Alzheimer's Disease: A Systematic Review
Hulshof, L. A., van Nuijs, D., Hol, E. M., & Middeldorp, J. (2022) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2022.899251 · Cited by 66
Dias, D., Portugal, C. C., Relvas, J. B., & Socodato, R. (2025) · Cells · doi:10.3390/cells14040243 · Cited by 71
A novel systems biology approach to evaluate mouse models of late-onset Alzheimer’s disease
the MODEL-AD Consortium, Preuss, C., Pandey, R., Piazza, E., Fine, A., Uyar, A., Perumal, T., Garceau, D., Kotredes, K. P., Williams, H., et al. (2020) · Molecular Neurodegeneration · doi:10.1186/s13024-020-00412-5 · Cited by 63
Panitch, R., Hu, J., Chung, J., Zhu, C., Meng, G., Xia, W., Bennett, D. A., Lunetta, K. L., Ikezu, T., Au, R., et al. (2021) · Molecular Psychiatry · doi:10.1038/s41380-021-01266-z · Cited by 59
Complement-mediated synapse loss in Alzheimer’s disease: mechanisms and involvement of risk factors
Wen, L., Bi, D., & Shen, Y. (2023) · Trends in Neurosciences · doi:10.1016/j.tins.2023.11.010 · Cited by 64
Hishimoto, A., Pletnikova, O., Lang, D. L., Troncoso, J. C., Egan, J. M., & Liu, Q.-R. (2019) · Alzheimer's Research & Therapy · doi:10.1186/s13195-019-0475-2 · Cited by 62
The roles of astrocytic phagocytosis in maintaining homeostasis of brains
Lee, S. Y., & Chung, W. (2020) · Journal of Pharmacological Sciences · doi:10.1016/j.jphs.2020.12.007 · Cited by 60
Self-citationPinto‐Benito, D., Paradela‐Leal, C., Ganchala, D., de Castro‐Molina, P., & Arévalo, M. (2022) · Glia · doi:10.1002/glia.24163 · Cited by 60
Czuba, E., Steliga, A., Lietzau, G., & Kowiański, P. (2017) · Metabolic Brain Disease · doi:10.1007/s11011-017-0015-3 · Cited by 62
Targeting Alzheimer's disease with gene and cell therapies
Loera‐Valencia, R., Piras, A., Ismail, M.-A.-M., Manchanda, S., Eyjolfsdottir, H., Saido, T. C., Johansson, J., Eriksdotter, M., Winblad, B. G., & Nilsson, P. (2018) · Journal of Internal Medicine · doi:10.1111/joim.12759 · Cited by 59
Iannucci, J., Sen, A., & Grammas, P. (2021) · Current Issues in Molecular Biology · doi:10.3390/cimb43010018 · Cited by 57
Central nervous system cholesterol metabolism in health and disease
Ho, W. Y., Hartmann, H., & Ling, S. (2022) · IUBMB Life · doi:10.1002/iub.2662 · Cited by 58
Exploring the dual character of metformin in Alzheimer's disease
Ning, P., Luo, A., Mu, X. L., Xu, Y., & Li, T. X. (2022) · Neuropharmacology · doi:10.1016/j.neuropharm.2022.108966 · Cited by 51
APOE ε4 genotype-dependent cerebrospinal fluid proteomic signatures in Alzheimer’s disease
Konijnenberg, E., Tijms, B. M., Gobom, J., Dobričić, V., Bos, I., Vos, S. J. B., Tsolaki, M., Verhey, F. R. J., Popp, J., Martínez‐Lage, P., et al. (2020) · Alzheimer s Research & Therapy · doi:10.1186/s13195-020-00628-z · Cited by 50
The role of genetic risk factors of Alzheimer’s disease in synaptic dysfunction
Fu, W.-Y., & Ip, N. Y. (2023) · Seminars in Cell & Developmental Biology · doi:10.1016/j.semcdb.2022.07.011 · Cited by 48
Cacciaglia, R., Molinuevo, J. L., Sánchez‐Benavides, G., Falcón, C., Gramunt, N., Brugulat‐Serrat, A., Grau‐Rivera, O., Gispert, J. D., & Study, F. T. A. (2018) · Human Brain Mapping · doi:10.1002/hbm.24306 · Cited by 49
Contribution of astrocytes to metabolic dysfunction in the Alzheimer’s disease brain
Zulfiqar, S., Garg, P., & Nieweg, K. (2019) · Biological Chemistry · doi:10.1515/hsz-2019-0140 · Cited by 46
Petek, B., Villa‐Lopez, M., Loera‐Valencia, R., Gereñu, G., Winblad, B. G., Kramberger, M. G., Ismail, M. A. M., Eriksdotter, M., & Ptacek, S. G. (2018) · Journal of Internal Medicine · doi:10.1111/joim.12838 · Cited by 47
APOE4 genotype exacerbates the depression-like behavior of mice during aging through ATP decline
Fang, W., Xiao, N., Zeng, G., Bi, D., Dai, X., Mi, X., Ye, Q., Chen, X., & Zhang, J. (2021) · Translational Psychiatry · doi:10.1038/s41398-021-01631-0 · Cited by 42
Targeting Apolipoprotein E for Alzheimer’s Disease: An Industry Perspective
Suidan, G. L., & Ramaswamy, G. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20092161 · Cited by 42
Raman, S., Brookhouser, N., & Brafman, D. A. (2020) · Neurobiology of Disease · doi:10.1016/j.nbd.2020.104788 · Cited by 41
Knowing the enemy: strategic targeting of complement to treat Alzheimer disease
Tenner, A. J., & Petrisko, T. J. (2025) · Nature Reviews Neurology · doi:10.1038/s41582-025-01073-y · Cited by 49
The Role of Apolipoprotein E Isoforms in Alzheimer’s Disease
Roda, A. R., Montoliu‐Gaya, L., & Villegas, S. (2019) · Journal of Alzheimer s Disease · doi:10.3233/jad-180740 · Cited by 41
Crespo‐Castrillo, A., García‐Segura, L. M., & Arévalo, M. (2020) · Journal of Neuroinflammation · doi:10.1186/s12974-020-1719-6 · Cited by 40
APOEgene and neuropsychiatric disorders and endophenotypes: A comprehensive review
Forero, D. A., López‐León, S., González‐Giraldo, Y., Dries, D. R., Pereira‐Morales, A. J., Jiménez, K. M., & Franco‐Restrepo, J. E. (2016) · American Journal of Medical Genetics Part B Neuropsychiatric Genetics · doi:10.1002/ajmg.b.32516 · Cited by 38
Hirota, Y., Sakakibara, Y., Ibaraki, K., Takei, K., Iijima, K., & Sekiya, M. (2022) · Brain Communications · doi:10.1093/braincomms/fcac286 · Cited by 41
Metadata
- Authors
- Chung, W.-S., Verghese, P. B., Chakraborty, C., Joung, J., Hyman, B. T., Ulrich, J. D., Holtzman, D. M., & Barres, B. A.
- Affiliations
- Stanford Medicine (US)
- Hope Center for Neurological Disorders (US)
- Massachusetts General Hospital (US)
- ORCID
- Venue
- Proceedings of the National Academy of Sciences
- Publisher
- National Academy of Sciences
- Published
- 2016-08-24
- Volume
- 113
- Issue
- 36
- Pages
- 10186-10191
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- PMC
- PMC5018780
- OpenAlex
- W2514110735
- Cited by
- 242
- References
- 50
- Citations by year
- 2026: 13 · 2025: 22 · 2024: 28 · 2023: 13 · 2022: 22 · 2021: 29 · 2020: 35 · 2019: 23 · 2018: 31 · 2017: 22 · 2016: 4
- FWCI
- 21.30
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Proceedings of the National Academy of Sciences (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- HHS | NIH | National Eye Institute (K99EY024690)
- HHS | National Institutes of Health (5 R21NS072556, R01 NS090934, R01 AG047644)
- National Research Foundation of Korea (NRF-2016M3C7A1905391, NRF-2016R1C1B3006969)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Keywords
- apolipoprotein E, APOE isoforms, APOE ε4, APOE2, astrocytes, synaptic pruning, phagocytosis, C1q, complement system, Alzheimer's disease risk, hippocampus, neurodegeneration
- MeSH terms
- Alleles, Alzheimer Disease, Animals, Astrocytes, Gene Expression Regulation, Genotype, Hippocampus, Humans, Mice, Transgenic, Neuronal Plasticity, Phagocytosis, Synapses, Complement C1q, Genetic Predisposition to Disease, Mice, Apolipoprotein E3, Apolipoprotein E4, Apolipoprotein E2, Gene Knock-In Techniques
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
